3.67

4.18% -0.16

Pre-market: 3.66 -0.010 -0.27%

Incannex Healthcare Inc (IXHL)

Overview News Price History Why IXHL Down? Discussions Forecast

Incannex Healthcare Inc stock is traded at $3.67, with a volume of 291.12K. It is down -4.18% in the last 24 hours and down -7.32% over the past month. Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Previous Close:

$3.83

Open:

$3.9

24h Volume:

291.12K

Relative Volume:

0.61

Market Cap:

$43.91M

Revenue:

$12,000

Net Income/Loss:

$-48.50M

P/E Ratio:

-0.215

EPS:

-17.0687

Net Cash Flow:

$-19.78M

1W Performance:

+7.94%

1M Performance:

-7.32%

6M Performance:

-68.25%

1Y Performance:

-40.67%

1-Day Range:

$3.65

$4.01

1-Week Range:

$3.31

$4.22

52-Week Range:

$2.49

$49.80

Incannex Healthcare Inc Stock (IXHL) Company Profile

Name

Incannex Healthcare Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

61 409 840 786

Address

8 CENTURY CIRCUIT, NORWEST NSW

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

IXHL's Discussions on Twitter

Compare IXHL vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IXHL Incannex Healthcare Inc	3.67	43.91M	12,000	-48.50M	-19.78M	-17.07
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Incannex Healthcare Inc Stock (IXHL) Latest News

Jun 14, 2026

Why Did IXHL Stock Tank Over 32% Today? - Stocktwits

Jun 14, 2026

Jun 13, 2026

IXHL Forecast — Price Target — Prediction for 2027 - TradingView

Jun 13, 2026

Jun 12, 2026

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits

Jun 12, 2026

Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com - Investing.com Nigeria

Jun 10, 2026

Incannex Healthcare Secures Major Non-Dilutive R&D Funding - TipRanks

Jun 10, 2026

Incannex Healthcare Secures Over A$11 Million in Non-Dilutive Capital Through Australian R&D Tax Incentive Program - Quiver Quantitative

Jun 10, 2026

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility - The Manila Times

Jun 10, 2026

Incannex lines up A$11m in non‑dilutive cash to advance IHL‑42X study - Stock Titan

Jun 10, 2026

Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding - TradingView

Jun 10, 2026

Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan

Jun 10, 2026

Jun 09, 2026

Incannex Healthcare: Target Price Consensus and Analysts Recommendations | IQI | AU000000IHL8 - marketscreener.com

Jun 09, 2026

Incannex Healthcare Gains Independent Buy-Rated Research Coverage - TipRanks

Jun 09, 2026

Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan

Jun 09, 2026

Incannex Healthcare: Alliance Global Partners Starts Coverage with $18 Price Target - TradingView

Jun 09, 2026

Alliance Global initiates Incannex (IXHL) equity research coverage on key drug pipeline - Stock Titan

Jun 09, 2026

Jun 08, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Jun 08, 2026

$Incannex Healthcare (IXHL.US)$ [Onlooker][OK] - Moomoo

Jun 08, 2026

Jun 05, 2026